MedTrace Logo

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

NCT05358821 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2025-09-15

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.

Conditions

  • Huntington Disease

Interventions

DRUG

SAGE-718

SAGE-718 oral softgel lipid capsules

DRUG

Placebo

SAGE-718-matching oral capsules

Sponsors & Collaborators

  • Supernus Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-26
Primary Completion
2024-02-29
Completion
2024-04-10
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05358821 on ClinicalTrials.gov